AR099312A1 - Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza - Google Patents
Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenzaInfo
- Publication number
- AR099312A1 AR099312A1 ARP150100356A ARP150100356A AR099312A1 AR 099312 A1 AR099312 A1 AR 099312A1 AR P150100356 A ARP150100356 A AR P150100356A AR P150100356 A ARP150100356 A AR P150100356A AR 099312 A1 AR099312 A1 AR 099312A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- independently
- phenyl
- together form
- aryl
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 230000010076 replication Effects 0.000 title abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- -1 -N (R1a) 2 Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 abstract 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- WUMYBFXWUJTWTB-UHFFFAOYSA-N [hydroxy(methoxy)phosphoryl] phosphono hydrogen phosphate Chemical compound COP(O)(=O)OP(O)(=O)OP(O)(O)=O WUMYBFXWUJTWTB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 101150009274 nhr-1 gene Proteins 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002212 purine nucleoside Substances 0.000 abstract 1
- 239000002718 pyrimidine nucleoside Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940113082 thymine Drugs 0.000 abstract 1
- 229940035893 uracil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La solicitud divulga derivados de nucleósidos como inhibidores de la replicación del ARN de influenza. En particular, la solicitud divulga el uso de derivados de nucleósidos purínicos y pirimidínicos como inhibidores de replicación del ARN de influenza y composiciones farmacéuticas que contienen tales compuestos. Reivindicación 1: Un compuesto inhibidor de la replicación del ARN de influenza de fórmula (1) caracterizado porque: Y es H o P(=X)(R)(R); R es O-R¹ o NHR¹; R¹ es -C(R²ᵃ)(R²ᵇ)C(=O)OR³; R es N(R⁴)C(R²ᵃ)(R²ᵇ)C(=O)OR³, -OP(=O)(OH)OP(=O)(OH)OH, o -OR³; R¹ es H, haloalquilo inferior, o arilo, en donde el arilo es fenilo o naftilenilo, opcionalmente sustituido con uno o más de alquilo inferior, alquenilo inferior, alquinilo inferior, alcoxi inferior, halo, haloalquilo inferior, -N(R¹ᵃ)₂, acilamino, -SO₂N(R¹ᵃ)₂, -C(=O)R¹ᵇ, -SO₂(R¹ᶜ), -NHSO₂(R¹ᶜ), nitro, ciano, o R¹; cada R¹ᵃ es independientemente H o alquilo inferior; cada R¹ᵇ es independientemente -OR¹ᵃ o -N(R¹ᵃ)₂; cada R¹ᶜ es alquilo inferior; cada R²ᵃ y R²ᵇ es independientemente H, alquilo inferior, (CH₂)ʳN(R¹ᵃ)₂, hidroxialquilo inferior, -CH₂SH, -(CH₂)S(O)ₚMe, -(CH₂)ₙNHC(=NH)NH₂, (1H-indol-3-il)metilo, (1H-indol-4-il)metilo, -(CH₂)ₘC(=O)R¹ᵇ, arilo y arilalquilo inferior, en donde el arilo está opcionalmente sustituido con uno o más de hidroxi, alquilo inferior, alcoxi inferior, halo, nitro o ciano; m es 0, 1, ó 2; n es 1, 2, ó 3; p es 1 ó 2; r es 1 ó 2; o R²ᵃ es H y R²ᵇ y R⁴ juntos forman (CH₂)ₙ; cada R³ es independientemente H, alquilo inferior, haloalquilo inferior, fenilo o fenil-alquilo inferior, en donde el fenilo y el fenil-alquilo inferior están opcionalmente sustituidos con alcoxi inferior; o R³ y R¹ juntos forman CH₂; cada R⁴ es independientemente H, alquilo inferior; o R²ᵇ y R⁴ juntos forman (CH₂)₃; Rʷ, Rʸ, y Rᶻ son cada uno independientemente H, OH o F; Rˣ es H, OH, o F; o R³ y Rˣ juntos forman una unión; o R¹ y Rˣ juntos forman una unión; X es O ó S; la Base es uracilo, citosina, guanina, adenina, timina, o heterocicloalquilo, cada uno de los cuales puede estar opcionalmente sustituido con uno o más de hidroxi, alquilo inferior, alcoxi inferior, halo, nitro o ciano; con la condición de que si Rʷ es H, Rʸ es H, y Rᶻ es H, entonces Rˣ no es H; y con la condición de que la fórmula (1) no es ((2R,3R,4R,5R)-5-(4-amino-2-oxopirimidin-1(2H)-il)-2-(difluorometil)-4-fluoro-3-hidroxitetrahidrofuran-2-il)metil tetrahidrógeno trifosfato; o una sal farmacológicamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936569P | 2014-02-06 | 2014-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099312A1 true AR099312A1 (es) | 2016-07-13 |
Family
ID=53774368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100356A AR099312A1 (es) | 2014-02-06 | 2015-02-06 | Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9370569B2 (es) |
| EP (1) | EP3102215B1 (es) |
| JP (1) | JP6581100B2 (es) |
| KR (1) | KR102327464B1 (es) |
| CN (1) | CN105979951B (es) |
| AR (1) | AR099312A1 (es) |
| AU (1) | AU2015213791B2 (es) |
| CA (1) | CA2945693C (es) |
| CL (1) | CL2016001973A1 (es) |
| CR (1) | CR20160400A (es) |
| EA (1) | EA033866B1 (es) |
| IL (1) | IL246929B (es) |
| MA (1) | MA39317A1 (es) |
| MX (1) | MX374191B (es) |
| PE (1) | PE20170203A1 (es) |
| PH (1) | PH12016501567B1 (es) |
| SG (1) | SG11201606368WA (es) |
| TW (1) | TWI620755B (es) |
| WO (1) | WO2015120237A2 (es) |
| ZA (1) | ZA201605979B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57843B1 (sr) | 2014-02-06 | 2018-12-31 | Heptares Therapeutics Ltd | Biciklična aza jedinjenja kao agonisti muskarinskog receptora m1 |
| KR102327464B1 (ko) * | 2014-02-06 | 2021-11-16 | 리보사이언스 엘엘씨 | 인플루엔자 rna 복제의 저해제로서의 4'-다이플루오로메틸 치환된 뉴클레오사이드 유도체 |
| MA41213A (fr) * | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| CN106543220A (zh) | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| CN106539810B (zh) * | 2015-09-16 | 2021-03-09 | 济南高合医疗科技有限公司 | 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途 |
| EP3661513A4 (en) * | 2017-07-31 | 2021-07-14 | January Therapeutics, Inc. | ORGANOPHOSPHATE DERIVATIVES |
| CN111434671B (zh) * | 2019-01-11 | 2023-07-11 | 凯思凯迪（上海）医药科技有限公司 | 肝脏特异性ampk激动剂及其制法和应用 |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| US11198699B2 (en) * | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| WO2020223530A1 (en) * | 2019-04-30 | 2020-11-05 | Cure Biopharma Inc. | Gemcitabine prodrugs |
| EP3962919A4 (en) * | 2019-05-03 | 2023-06-28 | Terns Pharmaceuticals, Inc. | Compounds for treating cancer |
| JP7429799B2 (ja) | 2020-02-18 | 2024-02-08 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| WO2022266384A1 (en) * | 2021-06-17 | 2022-12-22 | Terns Pharmaceuticals, Inc. | Methods for treating cancer |
| KR20240049311A (ko) | 2021-08-18 | 2024-04-16 | 길리애드 사이언시즈, 인코포레이티드 | 인지질 화합물 및 이의 제조 및 사용 방법 |
| PE20250684A1 (es) * | 2022-03-15 | 2025-03-04 | Rome Therapeutics Inc | Compuestos y metodos para el tratamiento de enfermedades |
| WO2024103016A1 (en) * | 2022-11-11 | 2024-05-16 | Rome Therapeutics, Inc. | 4'-halomethyl-cytidine phosphoramidates and related compounds and their use in treating medical conditions |
| CN119837893B (zh) * | 2025-03-24 | 2025-07-04 | 中国农业大学 | 5-氟-2′-脱氧胞苷在制备抗菌药物中的用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192749A (en) * | 1990-05-21 | 1993-03-09 | Syntex (U.S.A.) Inc. | 4'-substituted nucleosides |
| KR100905221B1 (ko) * | 2000-10-18 | 2009-07-01 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드 |
| US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| US20040229840A1 (en) | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| AU2012358803C1 (en) | 2011-12-22 | 2019-12-19 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN106749272B (zh) * | 2012-03-13 | 2019-08-30 | 吉利德科学公司 | 用于抗病毒治疗的2’-取代的卡巴-核苷类似物 |
| JP6430364B2 (ja) * | 2012-03-21 | 2018-11-28 | アリオス バイオファーマ インク． | 置換されたヌクレオシド、ヌクレオチドおよびそのアナログ |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CA2873315A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharamaceuticals, Inc. | D-amino acid compounds for liver disease |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| PE20151433A1 (es) | 2012-12-21 | 2015-10-16 | Alios Biopharma Inc | Nucleosidos sustituidos, nucleotidos y analogos de los mismos |
| AU2014302711A1 (en) | 2013-06-26 | 2015-12-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9862743B2 (en) * | 2013-10-11 | 2018-01-09 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| KR102327464B1 (ko) * | 2014-02-06 | 2021-11-16 | 리보사이언스 엘엘씨 | 인플루엔자 rna 복제의 저해제로서의 4'-다이플루오로메틸 치환된 뉴클레오사이드 유도체 |
-
2015
- 2015-02-06 KR KR1020167024454A patent/KR102327464B1/ko active Active
- 2015-02-06 SG SG11201606368WA patent/SG11201606368WA/en unknown
- 2015-02-06 EA EA201691554A patent/EA033866B1/ru not_active IP Right Cessation
- 2015-02-06 US US14/615,928 patent/US9370569B2/en active Active
- 2015-02-06 PE PE2016001288A patent/PE20170203A1/es unknown
- 2015-02-06 WO PCT/US2015/014762 patent/WO2015120237A2/en not_active Ceased
- 2015-02-06 AR ARP150100356A patent/AR099312A1/es unknown
- 2015-02-06 AU AU2015213791A patent/AU2015213791B2/en active Active
- 2015-02-06 CA CA2945693A patent/CA2945693C/en active Active
- 2015-02-06 TW TW104104136A patent/TWI620755B/zh not_active IP Right Cessation
- 2015-02-06 EP EP15746437.1A patent/EP3102215B1/en active Active
- 2015-02-06 JP JP2016550192A patent/JP6581100B2/ja active Active
- 2015-02-06 CR CR20160400A patent/CR20160400A/es unknown
- 2015-02-06 CN CN201580007707.8A patent/CN105979951B/zh not_active Expired - Fee Related
- 2015-02-06 PH PH1/2016/501567A patent/PH12016501567B1/en unknown
- 2015-02-06 MX MX2016010105A patent/MX374191B/es active IP Right Grant
- 2015-02-06 MA MA39317A patent/MA39317A1/fr unknown
-
2016
- 2016-06-20 US US15/187,014 patent/US10092649B2/en active Active
- 2016-07-25 IL IL246929A patent/IL246929B/en active IP Right Grant
- 2016-08-05 CL CL2016001973A patent/CL2016001973A1/es unknown
- 2016-08-29 ZA ZA2016/05979A patent/ZA201605979B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099312A1 (es) | Derivados de nucleósidos sustituidos con 4-difluorometil como inhibidores de la replicación del arn de influenza | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| MX386726B (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
| PE20161443A1 (es) | Compuestos | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| MX375625B (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| GEP201706793B (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| CR20190156A (es) | Derivados de bipirazol como inhibidores jak | |
| MA38347A1 (fr) | Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak) | |
| PE20050462A1 (es) | COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5) | |
| GT201400301A (es) | 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| AR096235A1 (es) | Arilquinazolinas | |
| IN2015DN00538A (es) | ||
| SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| MA40219B1 (fr) | Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| MX2015015786A (es) | Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas. | |
| NZ629037A (en) | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same | |
| CU20170123A7 (es) | Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b | |
| HN2011003482A (es) | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb) | |
| TW200626605A (en) | Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors | |
| MX2016015959A (es) | Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3. | |
| PE20061012A1 (es) | Derivados piperidinil piperazina como inhibidores de receptores quiomicina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |